| gap-pubmed-20260410- | What triggers the breakdown of B cell-mediated tolerance that leads to pathogeni | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do B cells mechanistically orchestrate tolerance to AQP4 and prevent autoimm | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does somatic mosaicism contribute to ephrinB2-EphB4-RASA1-related cerebrovas | open | 0.74 | 0.00 | 2026-04-10 | 0 | | cerebrovascular-development |
| gap-pubmed-20260410- | What are the molecular mechanisms by which ephrinB2-EphB4-RASA1 mutations cause | open | 0.85 | 0.00 | 2026-04-10 | 0 | | cerebrovascular-development |
| gap-pubmed-20260410- | Does HSV-1-mediated mitochondrial DNA deletion causally contribute to AD pathoge | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether HSV-1 promotes or attenuates apoptosis at different life | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does HSV-1 selectively target AD susceptibility genes versus other cellular | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Is efferocytosis failure due to defective 'eat-me' signals or impaired microglia | open | 0.85 | 0.00 | 2026-04-10 | 0 | | cellular-immunology |
| gap-debate-20260410- | What are the region-specific expression patterns and functions of GPR32 across b | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroanatomy |
| gap-debate-20260410- | Do GPR32 superagonists cause receptor desensitization that limits therapeutic ef | open | 0.80 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | What determines blood-brain barrier penetration kinetics for specialized pro-res | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | Does enhanced microglial activation via APOE-TREM2 modulation cause harmful neur | open | 0.85 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | What is the structural basis and druggability of the APOE-TREM2 protein-protein | open | 0.79 | 0.00 | 2026-04-10 | 0 | | structural-biology |
| gap-debate-20260410- | Is APOE4's reduced lipid binding pathogenic or a compensatory evolutionary adapt | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Can lipid nanoemulsions achieve APOE4-selective binding without affecting APOE2/ | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can TET2-mediated demethylation overcome established epigenetic memory in chroni | open | 0.71 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-debate-20260410- | How do P2Y1/P2X7 receptor ratios mechanistically control astrocyte phenotype swi | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cell-signaling |
| gap-debate-20260410- | What are the tissue-specific and disease-context variations in astrocyte reactiv | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | Does HK2-driven metabolic reprogramming causally determine astrocyte phenotype o | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do methylation effects on TDP-43 vary between different cell types and ALS-F | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Why did Arimoclomol fail primary endpoints despite showing biomarker effects in | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | Do arginine methylations uniformly reduce RNA binding or have site-specific vari | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What is the therapeutic window between insufficient and toxic levels of TDP-43 a | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can mitochondrial-lysosomal contact site engineering bypass upstream autophagy d | open | 0.75 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | What determines cell-type specificity of autophagy dysfunction across different | open | 0.78 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Are autophagy-lysosome defects primary drivers or downstream consequences in spo | partially_addressed | 0.92 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Does TRPML1 enhancement cause therapeutic benefit or paradoxical lysosomal dysfu | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can pharmacological connexin-43 upregulation achieve therapeutic benefit without | open | 0.85 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | What determines the directionality and selectivity of mitochondrial transfer bet | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | Do alternative mitochondrial transfer pathways compensate when connexin-43 is kn | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What is the relative contribution of connexin-43 gap junctions vs tunneling nano | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | Can cell-type specific circadian disruption selectively reduce neuroinflammatory | open | 0.71 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | How do stress granules mechanistically amplify inflammatory signals between micr | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What are the specific molecular pathways by which astrocytic lipid droplets fuel | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-debate-20260410- | Do microglia and astrocytes exhibit synchronized or phase-separated circadian in | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What is the temporal sequence of gut barrier dysfunction relative to CNS α-synuc | open | 0.80 | 0.00 | 2026-04-10 | 0 | | pathophysiology |
| gap-debate-20260410- | Can vagal nerve stimulation combined with GLP-1R agonists synergistically enhanc | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | What are the specific bacterial strains and metabolites that prime NLRP3 inflamm | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can adenosine A2A receptor modulation simultaneously improve sleep homeostasis a | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How does orexin receptor 2 selectivity affect microglial activation states in vi | open | 0.75 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | What are the causal relationships between AQP4 polarization changes and protein | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Does human glymphatic function show clinically relevant circadian variation like | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can existing heparanase inhibitors selectively target pathological tau without d | open | 0.71 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | How do regional P2Y12 expression differences mechanistically control tufted astr | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | What is the causal relationship between AQP4 mislocalization and tau strain-spec | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | Do PSP and CBD tau strains have distinct heparan sulfate binding specificities t | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How can syndecan-1 upregulation be achieved pharmacologically without disrupting | open | 0.71 | 0.00 | 2026-04-10 | 0 | | vascular-biology |
| gap-debate-20260410- | What are the optimal circadian timing protocols for orexin receptor modulation t | open | 0.75 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | How can PDGFR-β signaling be selectively biased toward contractility pathways wh | open | 0.78 | 0.00 | 2026-04-10 | 0 | | pharmacology |